Drug Profile

Research programme: killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapies - Verismo Therapeutics

Alternative Names: KIR-CAR T cell therapies - Verismo Therapeutics

Latest Information Update: 30 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Verismo Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Dec 2024 Verismo Therapeutics has been acquired by HLB Innovation
21 Jun 2022 Verismo Therapeutics and University of Pennsylvania agree to co-develop KIR-CAR T cell therapy for Solid tumours
19 Oct 2021 Early research in Solid tumours in USA (Parenteral) as of October 2021 (Verismo Therapeutics pipeline; October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com